Compare Simon Property Group Inc (SPG) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Simon Property Group Inc vs Tango Therapeutics Inc. — how do they compare? Simon Property Group Inc trades at $200.17 (market cap $64.92B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Simon Property Group Inc is far larger — about 17.3× Tango Therapeutics Inc.'s market cap, and Simon Property Group Inc pays a 4.44% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Simon Property Group Inc for 100 Days and Tango Therapeutics Inc. for 0 Days on average.
| SPG | TNGX | |
|---|---|---|
Market Cap | $64.92B | $3.75B |
Volume | 1,919,136 | 9,619,106 |
Sector | Real Estate | Health |
52-Week High | $236.70 | $32.90 |
52-Week Low | $173.35 | $7.50 |
Typical Hold Time | 100 Days | 0 Days |
Enterprise Value | $93.37B | $2.77B |
Dividend Yield | 4.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPG trades at $198.70, down 1.35% with bearish technical signals from moving averages and ADX indicators. The REIT maintains strong fundamentals with Q4 2025 EPS beating expectations at $9.35 versus $1.90, though Q2 2026 missed at $1.49 versus $1.64. Recent news highlights strong leasing demand and a new $800 million debt issuance, while directors made small stock purchases in late September 2026.
SPG presents a mixed outlook with robust profitability metrics like 66.57% net margin and 135.7% ROE offset by negative net cash flow and high debt levels. The consensus price target of $218.45 suggests 10% upside potential, but rising bond yields and $2B in 2024 debt maturities pose headwinds for the retail REIT sector.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
